The 94th Annual Meeting of the Japanese Gastric Cancer Association

Call for Abstracts

Illustration of Yokohama

Abstract Submission Period

Abstracts for oral, poster or video presentation

Wednesday, 14th July 2021 – Friday, 31st August 2021
Final deadline has been extended to Noon,(Wed) 15th September 2021.
Final deadline has been extended to 23:59 (JST), Thursday, 30th September 2021.
Final deadline has been extended to 23:59 (JST), Friday, 8th October 2021.
Abstract Submission is now closed. Thank you for your submission.

Presentation Style

Please select one of the presentation styles below:

  • Oral presentation
  • Poster presentation (Time for oral presentation available)
  • Video presentation

    * The detailed information for preparation of the presentation slides and data will be announced after the notification of the acceptance or rejection.

Presentation Categories

Please select the most appropriate category for your presentation.

Symposium / Video Symposium / Panel discussion / Workshop / Video Workshop categories

Symposium
  • State of the art of therapeutic strategy for Siewert type2 esophagogastric junction cancer

    The incidence of esophagogastric junction cancer has been increasing and the surgical approach method and the extent of lymph node dissection according to the invasion length of tumor toward the esophagus were reported in a Japanese multi-center retrospective cohort study. In this symposium, the panelists should discuss the optimal therapeutic strategies based on their own multidisciplinary treatments, the surgical approach method, the extent of the resection of the stomach and the esophagus and lymph node dissection, the reconstruction method. We hope that the discussion of this symposium will be a foundation for the therapeutic strategy of this entity.

  • Now, we ask it over again. What are the indication and the significance of the conversion surgery for advanced gastric cancer?

    Some previous studies reported the indication and the significance of the conversion surgery for advanced gastric cancer. However, the background of the patients with advanced gastric cancer is various and there, it is difficult to conduct a uniform therapeutic strategy for this population. Please discuss what kind of patient is adaptive, what kind of the therapy is appropriate, how many times of therapy is optimal to lead the conversion surgery. Moreover, what is the predictive factor for the conversion surgery? Additionally, what is the best adjuvant therapy? Finally, please discuss the prognostic factor of the conversion surgery.

  • Elucidation and application of molecular biologic abnormality for therapeutic strategy in gastric cancer

    Based on the results of the Cancer Genome Atlas (TCGA) project, biomolecular characteristics of gastric cancer is divided into 4 classifications: Epstein-Barr virus positive; microsatellite instability; genomically stable; chromosomal instability. Please clarify clinical characteristics and establish more comprehensive therapeutic strategy for each biomolecular characteristics of gastric cancer based on the therapeutic method and the therapeutic outcomes.

  • What is the useful biomarker for gastric cancer based on the therapeutic outcomes using the newly developed regimens?

    Recently, several kinds of drugs and regimes have been newly developed and frequently used for gastric cancer on daily practice. However, the therapeutic outcomes are not satisfactory for advanced gastric cancer, while the therapeutic outcomes of these newly developed treatments can be partly expected. If we can identify the prognostic biomarkers for gastric cancer, it may be possible to improve the therapeutic outcomes even for advanced gastric cancer. Therefore, please discuss and confirm the prognostic factors with clinical availability in this symposium.

  • To what extent can we improve the therapeutic outcomes of gastric cancer using genome medicine?

    Insurance coverage for genome medicine was allowed for several kinds of cancers since June 2019 in Japan, therefore, we can apply this method on daily clinical practice. This treatment can be allowed to perform after standard chemotherapies and it is said that the percentage of the patients who can receive the benefits from this system is about 10%. It is important to clarify to what extent can we improve the therapeutic outcomes of gastric cancer using genome medicine. Please present the present status and the therapeutic outcomes of genome medicine for gastric cancer in each institute to develop this system in gastric cancer treatment.

  • State of the art of pharmacotherapy for advanced gastric cancer

    Although pharmacotherapy for advanced gastric cancer has been progressing, the therapeutic outcome is unsatisfactory. Based on the results of several worldwide clinical studies, some regimens have been approved and listed as the first-line, the second-line and the third-line in the 6th Japanese Gastric Cancer Treatment Guidelines. Therefore, we can anticipate the more satisfactory outcome by using these newly developed regimens. In this symposium, please show the results of the international and Japanese clinical studies conducted in several clinical study groups and discuss what kind of regimens can be a standard regimen for advanced gastric cancer.

Video Symposium
  • Pros and cons of robotic surgery for gastric cancer

    Due to the insurance coverage of the robotic surgery for gastric cancer, the robotic gastrectomy has been robustly extending in Japan. What kind of gastrectomy and surgical procedure is the robotic gastrectomy beneficial for? How can we maximally bring out the knack of the robotic gastrectomy? What is the pitfall in the robotic gastrectomy? Please show the video with comprehensive explanation for the unexperienced young gastric surgeons to easily understand the difference from laparoscopic gastrectomy. And please clarify the pros and cons of the robotic surgery for gastric cancer.

  • Pitfall of laparoscopic gastrectomy for advanced gastric cancer

    Laparoscopic distal, proximal and total gastrectomy are recommended for cStage I gastric cancer based on the results of JCOG 0912 and 1401 in Japan. However, we do not have any data of laparoscopic gastrectomy for advanced gastric cancer in the nation-wide clinical study in Japan. Therefore, the results of JLSSG0901 is anticipated. By contrast, laparoscopic gastrectomy for advanced gastric cancer over cStage II is commonly performed in many institutes in Japan. What is the difference in the laparoscopic surgical procedure of gastric cancer between for early stage and advanced stage? What is the pitfall of the laparoscopic gastrectomy for advanced gastric cancer? How can we ensure the curability and oncological safety? Please show us the video with reasonable explanation.

  • The steady surgical procedure for esophagogastric junction cancer (Siewert type 2)

    Therapeutic strategy for esophagogastric junction cancer has been gradually revealed. However, the surgical procedures remain to have a wide variety. From the viewpoint of oncology, what kind of the resected extent of the esophagus and the stomach, and the lymph node dissection extent are appropriate for what kind of the lesion? From the viewpoint of QOL, what kind of the reconstruction method is optimal? Please discuss and contribute the establishment of the highly qualified surgical procedure by showing the original video for esophagogastric junction cancer.

Panel Discussion
  • How advanced has the robotic surgery for gastric cancer? : Indication from the viewpoint of the therapeutic outcomes

    Due to the insurance coverage of the robotic surgery for gastric cancer, the robotic gastrectomy has been robustly extending in Japan. The knacks and pitfalls of this technique have been gradually realized and this surgery has taken a firm hold on the surgical procedure for gastric cancer. In the panel discussion, please show the short- and long-term outcomes and clarify the indication of this technique appropriately.

  • Indication and Impact of splenectomy/splenic hilar lymph node dissection preserving the spleen for proximal gastric cancer

    It is concluded that splenectomy should be avoided as it increases operative morbidity without improving survival in total gastrectomy for proximal gastric cancer that does not invade the greater curvature based on the results of JCOG0110. JCOG1809 study, which is a single-arm phase II trial to evaluate safety of laparoscopic total gastrectomy with spleen-reserving splenic hilar dissection for proximal gastric cancer invading the greater curvature, is going on. Now, it is a turning point of the therapeutic strategy for splenic hilar lymph node dissection in Japan. Please discuss the indication and impact of splenectomy/splenic hilar lymph node dissection preserving the spleen for proximal gastric cancer based on the surgical results in each institute.

  • New development for HER2 positive advanced gastric cancer

    A standard first-line therapeutic strategy for HER2 positive advanced gastric cancer is listed in the Japan Gastric Cancer Treatment Guideline (ver.5) based on ToGA study and widely employed for this entity. However, HER2 loss after administration of Herceptin and heterogeneity in the tumor remain to be problematic to improve the therapeutic outcomes. Additionally, trastuzumab deruxtecan (DS-8201) was developed as the third-line or after treatment for HER2 positive advanced gastric cancer and covered by Japanese insurance system. Please discuss the therapeutic strategy for HER2 positive advanced gastric cancer from various perspectives and make the foundation for the new treatments.

Workshop
  • To improve the therapeutic outcomes of ICI therapy for advanced gastric cancer: what is a new biomarker in this treatment?

    Two types of ICIs for advanced gastric cancer have been covered by Japanese insurance system based on ATTRACTION-2 study and CheckMate 649 study (Nivolumab for third-line treatment and first-line treatment) and on KEYNOTE-158 study (Pembrolizumab for MSI-high tumor). Although these ICIs are promising anti-PD-1 antibody, biomarkers for these ICIs have not been clearly identified. If we can obtain useful biomarkers, we may receive acceptable therapeutic outcomes. In this session, please present clinical and basic research outcomes as concerns biomarkers related with ICIs and discuss the therapeutic strategy on the next stage.

  • Indication and limitation of pharmacotherapy for elderly patients with advanced gastric cancer

    It is easily supposed that the number and incidence of elderly gastric cancer patients is increasing according to the progression of aging age in Japan. We sometimes encounter elderly gastric cancer patients who cannot be ideally administered adjuvant chemotherapy due to the unresectable far advanced stage by the delay of the accurate diagnosis and the remarkable delay of recovery after surgery due to their co-morbid disease. What is the indication of pharmacotherapy and what kind of the regimens are used for the elderly gastric cancer patients with several kinds of co-morbid diseases? Are therapeutic outcomes similar to those of gastric cancer patients in the other generation? Please face this highlighted problem and discuss the optimal strategy for the elderly.

Video Workshop
  • Invention of LECS for gastroduodenal tumors

    Previously, several methods of LECS have been developed in Japan. According to the site and the diameter of the tumor, some kinds of invention have been developed to improve the safety and curability. Accordingly, the indication of this technique have been extended. In some institutes, EFTR has been employed as an advanced medical care. Although the high incidence of postoperative complications is concerned due to the technical difficulty for duodenal tumors, the advanced technique and inventions may overcome the present status. Please show the video with meticulous explanation and discuss endeavor to develop safe and high quality technique of LECS.

  • Pitfall of splenic hilar lymph node dissection for proximal gastric cancer: laparoscopic surgery or robotic surgery

    JCOG1809 study, which is a single-arm phase II trial to evaluate safety of laparoscopic total gastrectomy with spleen-reserving splenic hilar dissection for proximal gastric cancer invading the greater curvature, is now going on. Please discuss the efforts to improve the quality of splenic hilar lymph node dissection with distinguished devices by presenting the fine video.

  • Invention of navigation surgery

    The fluorescent endoscopic surgery using ICG has been used for several kinds of cancers. This technique enables us to identify the sentinel lymph node, to confirm the residual lymph node to be dissected, to decide the optimal resection line of the stomach and to reconfirm the blood flow of the reconstructive organs. What is the present status of the navigation surgery using this technique for gastric cancer in each institute? What are the surgical benefits? Please show the comprehensive video to spread this technology widely by discussing the surgical outcomes.

  • Invention of ESD

    It has been a long time since ESD was introduced to general clinical practice. So far, many kinds of endoscopic techniques have been reported and now it is possible to perform ESD safely and steadily within an acceptable time frame. However, we sometimes have trouble dealing with appropriate ESD owing to the difficulty to obtain satisfactory operative field, to identify the accurate extension of a tumor and a recurrent case, etc. Please show us the endoscopic technique with sufficient countermeasures for such conventionally difficult case and discuss the therapeutic outcomes to apply these techniques on daily practice.

Oral / Video / Poster Categories

1Epidemiology
2Molecular biology
3Pathology
4Genomics
5Translational research
6Biomarker
7Tumor microenvironment
8AI
9Endoscopic therapy
10Endoscopic diagnosis
11Imaging diagnosis
12H.pylori
13Progression of gastric cancer
14Rare metastasis / Micrometastasis
15Intraoperative frozen section
16Cancer stem cell
17Clinical pathology
18Prognostic factor
19Precision medicine
20Clinical study
21Chemotherapy
22Neoadjuvant chemotherapy
23Adjuvant chemotherapy
24Second-line chemotherapy
25Third-line chemotherapy
26Intraperitoneal chemotherapy
27Molecular targeted therapy
28Immunotherapy
29Radiation therapy
30conversion surgery
31Surgery
32Laparoscopic surgery
33Robot surgery
34Function-preserving surgery
35Cytoreductive surgery
36LECS
37Surgical navigation
38Postoperative functional assessment
39Postgastrectomy syndrome
40Perioperative management
41Postoperative complications
42ERAS
43Navigation Surgery
44Peritoneal dissemination
45CART
46Stent placement
47Liver metastasis
48Recurrence
49Early gastric cancer
50Advanced gastric cancer
51Scirrhous gastric cancer
52Gastric stump carcinoma
53Multiple gastric cancers
54Gastric tube cancer
55Esophago-gastric junction cancer
56Gastric cancer in elderly patients
57AFP-producing gastric cancer
58EBV-related gastric cancer
59Gastrointestinal stromal tumor
60Malignant lymphoma
61Gastric neuroendocrine tumor
62Guidelines
63Clinical pathway
64Postoperative surveillance
65Long-term survival case after chemotherapy
66NST
67Outcome
68QOL assessment
69Cachexia
70Nutrition
71Obesity
72Case report
73Japanese Classification of Gastric Carcinoma
74Multidisciplinary treatment
75Palliative therapy
76Team approach
77Patient Advocacy
78MDT conference
79Medical cooperation
80Oral care
81Others

Abstract Acceptance or Rejection

Please note that the decision on abstract acceptance/rejection and presentation style (oral, poster or video) is left to the sole discretion of the Congress President.

Abstract Submission

Language for abstract

English

Language for presentation

English

Language for presentation slides

English

The number of characters

Title: up to 100 characters (including spaces)
Abstract: up to 1600 characters (including spaces)

Conflict of Interest Disclosure

The author is required to report applicable COI (Conflict of Interest) by completing the "Conflict of Interest Disclosure" part in the Abstract Submission process.

  • If there is no COI to disclose
  • If there is any COI to disclose

Inquiries

Secretariat of 94th Annual Meeting of The Japanese Gastric Cancer Association
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-94jgca[A]convention[D]co[D]jp( Please change [A] to @ and [D] to . )

page top